Full Press Release Details
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology.
BIIB
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Key Takeaway: Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis